SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Josephine Baker — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJosephine Baker
Date of birth1906-06-03
IdentifiersMRN HR-ML049-SYN-TD; SSN (made up) 000-49-3172
Document date1969-04-28
AuthorColette Ashby-Nwosu, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review: echocardiogram, cardiology consultation and breathlessness. [S]

History of Present Illness

Ms. Baker returns two weeks after intake and is seen the same day by Dr. Mbeki-Fontaine of cardiology after her echocardiogram this morning. She is still breathless, but she describes it more exactly now: a sudden need to take a deep breath, often while sitting still or talking, as if she cannot get enough air, which began two or three days after she left the hospital. It does not build with effort the way it did on the day of the heart attack, and she has had no chest pressure, palpitations, ankle swelling, cough or waking at night breathless. She has taken every dose of aspirin, ticagrelor, atorvastatin, metoprolol and lisinopril, and has not needed nitroglycerin. Her home blood pressure averages 136/82. She has been to two cardiac rehabilitation sessions; on the treadmill she was not limited by breath. She is sleeping a little better. [S]

ElementDetail
BreathlessnessAir hunger at rest and while talking, from two or three days after discharge; not exertional; no chest pain
EchocardiogramEjection fraction 52%; inferior hypokinesis; normal filling pressures
Home blood pressureAverage 136/82 mmHg
RehabilitationTwo sessions completed without limiting breathlessness
Lipoprotein(a)172 nmol/L

Review of Systems

SystemResultFinding
RespiratoryPositiveEpisodes of air hunger at rest; no cough, wheeze or night breathlessness
CardiovascularNegativeNo chest pain, palpitations, orthopnea or ankle swelling
Hematologic/lymphaticNegativeNo bleeding or unusual bruising
PsychiatricPositiveStill worried about money and her children; sleeping a little better

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route1969-03-24activeS
Ticagrelor 90 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route1969-03-24 to 1969-04-28completedS
Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet dailyOne tablet daily after a 600 mg loading doseOral route1969-04-28activeS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route1969-03-24activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route1969-03-24activeS
Lisinopril 5 mg oral tablet, one tablet dailyOne tablet dailyOral route1969-03-24 to 1969-04-28completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route1969-04-28activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route1969-03-24activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1969-04-28Body height168cmS
1969-04-28Body weight59.6kgS
1969-04-28Body mass index (BMI) [Ratio]21.1kg/m2S
1969-04-28Systolic blood pressure136mm[Hg]S
1969-04-28Diastolic blood pressure82mm[Hg]S
1969-04-28Heart rate62/minS
1969-04-28Respiratory rate16/minS
1969-04-28Body temperature36.7CelS
1969-04-28Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1969-04-28Lipoprotein a [Moles/volume] in Serum or Plasma172nmol/L125 nmol/L or higher is a risk-enhancing levelHighS
1969-04-28Left ventricular Ejection fraction52%50-70%NormalS

Physical Exam

Vital signs recorded on 1969-04-28; see the Vital Signs section. [S]

SystemFinding
GeneralWell; talking in full sentences; blood pressure 136/82, pulse 62; oxygen saturation 98% on room air; weight 59.6 kg
NeckJugular venous pressure not raised
CardiovascularRegular rhythm; normal heart sounds; no murmur or gallop; right radial access site healed
RespiratoryClear; no crackles or wheeze
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion and tiredness since discharge three weeks after the heart attack, without chest pain at rest; cause to be determined (heart function, ischemia, anemia, medicine effect or deconditioning)resolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology attributed it to ticagrelor.
Coronary artery disease after a non-ST-elevation myocardial infarction three weeks before intake, treated with one drug-eluting stent to the right coronary artery; synthetic modern episode linked to the documented heart attack of March 1912activeconfirmed I25.10S — Synthetic modern diagnosis; the 1969 heart attack remains D in the history.
High blood pressure, found during the hospital stay for the heart attackactiveconfirmed I10S — Synthetic modern diagnosis; no claim about her real blood pressure.
Absence of the uterus after an emergency hysterectomy at about 35, during a long, grave illness after the loss of a pregnancy; whether the ovaries were removed is not known; counted as a possible early menopause when weighing her cardiovascular riskactiveprovisional Z90.710S — Synthetic modern status linked to the retrospective account of a hysterectomy in 1941 or 1942; the operation itself rests on one secondary source.
Breathlessness from ticagrelor: a common, harmless side effect, resolved after the change to clopidogrelactiveconfirmed T45.525AS — Synthetic diagnosis at the second visit; resolved at the third visit after the switch.
Raised lipoprotein(a), 172 nmol/L, an inherited risk-enhancing factoractiveconfirmed E78.41S — Synthetic result measured once at the second visit.
Financial strain: heavy debts after the loss of her home and estate, with income only from performing, which she has stopped while she recoversactiveconfirmed Z59.86S — Synthetic social need anchored to her documented debts and the loss of Les Milandes.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (seated, average of two readings; home readings)Every visitCompleted today136/82 mmHg; home average 136/82; above target
ExaminationWeight, BMI and physical activityEvery visitCompleted today59.6 kg, BMI 21.1; two rehabilitation sessions
Medication safetyAdherence: aspirin and P2Y12 inhibitor through the dual antiplatelet window, high-intensity statin, beta-blocker, ACE inhibitorEvery visitCompleted todayNo missed doses; ticagrelor stopped for breathlessness and replaced by clopidogrel with a loading dose
Medication safetyBleeding on dual antiplatelet therapy (symptoms, hemoglobin when indicated)Every visitCompleted todayNo bleeding; hemoglobin 12.2 g/dL at intake
ImagingEchocardiogram for left ventricular functionAfter the infarction if not done or if function was reduced; then only with clinical changeCompleted todayEjection fraction 52%, inferior hypokinesis, normal filling pressures, no thrombus
LaboratoryLipoprotein(a)OnceCompleted today172 nmol/L, a risk-enhancing level
LaboratoryLipid panelFour to eight weeks after a statin start or change, then every three to twelve monthsOrderedLDL 84 mg/dL at intake, only three weeks after atorvastatin 80 mg was started; panel ordered with the potassium check in one to two weeks
LaboratoryMetabolic panel (potassium, creatinine, eGFR) on an ACE inhibitorOne to two weeks after a start or dose change, then every six to twelve monthsOrderedPotassium 4.4, creatinine 0.82 mg/dL at intake; lisinopril raised today, panel due in one to two weeks
LaboratoryHemoglobin A1c (no diabetes)Yearly screeningUp to date5.6% at intake
ExaminationECG and troponinOnly with new or changing symptomsNot indicatedNo angina or change in symptoms suggesting ischemia; ECG at intake showed no acute change
SurveyAngina status (Seattle Angina Questionnaire-7)At intake and every few months in the first yearUp to date70 at intake; next at the next visit
SurveyDepression screen (PHQ-2, then PHQ-9)After the infarction and periodicallyUp to datePHQ-9 7 at intake with item 9 scored 0; repeat at about twelve weeks
ExaminationTobacco useEvery visitCompleted todayNever smoker
ReferralCardiac rehabilitationWithin weeks of the infarction; 36 sessionsCompleted todayEnrolled; two sessions completed
Self-managementSelf-management: chest-pain action plan, nitroglycerin, women's warning symptomsEvery visitCompleted todayAction plan reviewed; nitroglycerin not needed
Medication safetyMedicine and visit costsEvery visitCompleted todayClopidogrel is a low-cost generic; social worker next week
ReferralCardiology consultationAfter the infarctionCompleted todaySeen by Dr. Mbeki-Fontaine today

Goal progress:

Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026)

Follow-up: Metabolic panel in one to two weeks. Review in four weeks. Call for breathlessness that worsens, bleeding, or lightheadedness; call 911 for chest pain not relieved five minutes after one nitroglycerin. Next scheduled visit 1969-05-26: four-week review after the change to clopidogrel: breathlessness, blood pressure, potassium and kidney function, and cardiac rehabilitation. [S]